1
|
Arring NM, Millstine D, Barton DL, Lyons KS, Girardo M, Hutson A, Nail LM. Trends in integrative medicine and health consults: differences between cancer survivors and patients without cancer. Support Care Cancer 2020; 29:3103-3112. [PMID: 33057818 DOI: 10.1007/s00520-020-05815-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Accepted: 10/06/2020] [Indexed: 11/24/2022]
Abstract
OBJECTIVES The objectives were to compare patients with and without cancer who sought an integrative health (IH) consult and reasons for seeking a consult. DESIGN Descriptive cross-sectional study that employed a secondary analysis of an integrative health database supplemented by a retrospective medical record review. SETTING/LOCATION Integrative Medicine and Health program in a Southwestern United States academic medical center. SUBJECTS Eight hundred thirty-nine adults over the age of 18 seeking IH consultation. RESULTS The number of complementary therapies reported prior to consult were not significantly different between groups. The most reported complementary therapies used by cancer survivors were multivitamins, exercise, and turmeric. Patients without cancer reported significantly higher pain levels than cancer survivors. Cancer survivors reported significantly higher energy, sleep levels, overall health, spiritual wellbeing, and significantly better relationships compared to patients without cancer. Cancer survivors reported fatigue and cancer as the top reasons for IH consult. CONCLUSION Participants without cancer reported higher levels of pain and lower levels of energy, sleep, overall health, spiritual wellbeing, and relationships compared to cancer survivors. However, cancer survivors still reported levels of unmanaged symptoms. Complementary therapy use prior to IMH consult was similar between groups; however, IMH providers recommended more treatments for patients without cancer. Our results highlight that more evidence is needed to guide IMH recommendations, especially for cancer survivors who may still be in treatment. Additionally, our results support evidence-based recommendations that all cancer survivors should be assessed for complementary therapy use and provided counseling by qualified providers on their advantages and limitations.
Collapse
Affiliation(s)
- Noël M Arring
- School of Nursing, University of Michigan, 400 North Ingalls St, RM 4320, Ann Arbor, MI, 48108, USA. .,Department of Nursing, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ, 85054, USA.
| | - Denise Millstine
- Division of General Internal Medicine, Division of Women's Health Internal Medicine, Mayo Clinic, 13737 North 92nd Street, Scottsdale, AZ, 85260, USA
| | - Debra L Barton
- School of Nursing, University of Michigan, 400 North Ingalls St, RM 4320, Ann Arbor, MI, 48108, USA
| | - Karen S Lyons
- William F. Connell School of Nursing, Boston College, Maloney Hall, 140 Commonwealth Ave, Chestnut Hill, MA, 02467, USA
| | - Marlene Girardo
- Research Biostatistics Division, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ, 85259, USA
| | - Amy Hutson
- Department of Nursing, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ, 85054, USA
| | - Lillian M Nail
- Oregon Health & Science University, School of Nursing, 3455 SW US Veterans Hospital Rd, OR, 97239, Portland, USA
| |
Collapse
|
2
|
Ben-Arye E, Samuels N, Daher M, Turker I, Nimri O, Rassouli M, Silbermann M. Integrating Complementary and Traditional Practices in Middle-Eastern Supportive Cancer Care. J Natl Cancer Inst Monogr 2018; 2017:4617831. [PMID: 29140497 DOI: 10.1093/jncimonographs/lgx016] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Accepted: 07/25/2017] [Indexed: 02/06/2023] Open
Abstract
The Middle East is a promising arena in which researchers can explore the interchange between cross-cultural traditional medicine and supportive cancer care, as provided within an integrative oncology setting. Integrative oncology research and clinical practice in this part of the world have been focusing, for the most part, on the use of herbal medicine and mind-body-spiritual modalities, both of which are deeply rooted in traditional medical care. A regional, multinational, and interdisciplinary collaboration is currently being undertaken as part of the academic activities of the Middle-East Research Group in Integrative Oncology (MERGIO). This group is part of the Middle-East Cancer Consortium, a body supported by the National Cancer Institute. MERGIO currently facilitates a number of innovative educational, basic science, and clinical research projects that are investigating the effectiveness and safety of traditional herbal remedies. In order to create a structured, pragmatic "bedside-to-bench" and subsequent "back-to-bedside" approach, MERGIO has designed a patient-tailored integrative oncology model of supportive-palliative care. This approach addresses both patients' individual health belief models and the larger social-cultural-religious context, as defined by the health-related values of the patient's community.
Collapse
Affiliation(s)
- Eran Ben-Arye
- Integrative Oncology Program, The Oncology Service, Lin Medical Center, Clalit Health Services, Haifa and Western Galilee District, Israel; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Tal Center for Integrative Oncology, Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel; University of Balamand, Saint George Hospital, UMC, Beirut, Lebanon; Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey; Jordan Cancer Registry, Ministry of Health, Amman, The Hashemite Kingdom of Jordan; Shahid Beheshti University of Medical Sciences, Teheran, Iran; Middle East Cancer Consortium, Haifa, Israel
| | - Noah Samuels
- Integrative Oncology Program, The Oncology Service, Lin Medical Center, Clalit Health Services, Haifa and Western Galilee District, Israel; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Tal Center for Integrative Oncology, Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel; University of Balamand, Saint George Hospital, UMC, Beirut, Lebanon; Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey; Jordan Cancer Registry, Ministry of Health, Amman, The Hashemite Kingdom of Jordan; Shahid Beheshti University of Medical Sciences, Teheran, Iran; Middle East Cancer Consortium, Haifa, Israel
| | - Michel Daher
- Integrative Oncology Program, The Oncology Service, Lin Medical Center, Clalit Health Services, Haifa and Western Galilee District, Israel; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Tal Center for Integrative Oncology, Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel; University of Balamand, Saint George Hospital, UMC, Beirut, Lebanon; Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey; Jordan Cancer Registry, Ministry of Health, Amman, The Hashemite Kingdom of Jordan; Shahid Beheshti University of Medical Sciences, Teheran, Iran; Middle East Cancer Consortium, Haifa, Israel
| | - Ibrahim Turker
- Integrative Oncology Program, The Oncology Service, Lin Medical Center, Clalit Health Services, Haifa and Western Galilee District, Israel; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Tal Center for Integrative Oncology, Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel; University of Balamand, Saint George Hospital, UMC, Beirut, Lebanon; Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey; Jordan Cancer Registry, Ministry of Health, Amman, The Hashemite Kingdom of Jordan; Shahid Beheshti University of Medical Sciences, Teheran, Iran; Middle East Cancer Consortium, Haifa, Israel
| | - Omar Nimri
- Integrative Oncology Program, The Oncology Service, Lin Medical Center, Clalit Health Services, Haifa and Western Galilee District, Israel; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Tal Center for Integrative Oncology, Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel; University of Balamand, Saint George Hospital, UMC, Beirut, Lebanon; Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey; Jordan Cancer Registry, Ministry of Health, Amman, The Hashemite Kingdom of Jordan; Shahid Beheshti University of Medical Sciences, Teheran, Iran; Middle East Cancer Consortium, Haifa, Israel
| | - Maryam Rassouli
- Integrative Oncology Program, The Oncology Service, Lin Medical Center, Clalit Health Services, Haifa and Western Galilee District, Israel; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Tal Center for Integrative Oncology, Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel; University of Balamand, Saint George Hospital, UMC, Beirut, Lebanon; Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey; Jordan Cancer Registry, Ministry of Health, Amman, The Hashemite Kingdom of Jordan; Shahid Beheshti University of Medical Sciences, Teheran, Iran; Middle East Cancer Consortium, Haifa, Israel
| | - Michael Silbermann
- Integrative Oncology Program, The Oncology Service, Lin Medical Center, Clalit Health Services, Haifa and Western Galilee District, Israel; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Tal Center for Integrative Oncology, Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel; University of Balamand, Saint George Hospital, UMC, Beirut, Lebanon; Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey; Jordan Cancer Registry, Ministry of Health, Amman, The Hashemite Kingdom of Jordan; Shahid Beheshti University of Medical Sciences, Teheran, Iran; Middle East Cancer Consortium, Haifa, Israel
| |
Collapse
|